World Journal of Gastroenterology - Baishideng Publishing Group

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Hoffmann P, Jung V, Behnisch R, Gauss A. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis. World J Gastroenterol 2020; 26(46): 7367-7381 [PMID: 33362390 DOI: 10.3748/wjg.v26.i46.7367]
URL:	https://www.wjgnet.com/1007-9327/full/v26/i46/7367.htm

(253) (236) (0) (0) (0) (1) (6647) (36)

Number	Citing Articles
1	Apostolis Papaefthymiou, Spyros Potamianos, Antonis Goulas, Michael Doulberis, Jannis Kountouras, Stergios A Polyzos. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. Journal of Crohn's and Colitis 2022; 16(5) doi: 10.1093/ecco-jcc/jjab212
2	Athri Kodali, Chiugo Okoye, Dhadon Klein, Iman Mohamoud, Olawale O Olanisa, Panah Parab, Priti Chaudhary, Sonia Mukhtar, Ali Moradi, Pousette Hamid. Crohn’s Disease is a Greater Risk Factor for Nonalcoholic Fatty Liver Disease Compared to Ulcerative Colitis: A Systematic Review. Cureus 2023; doi: 10.7759/cureus.42995
3	Lívia dos Remédios Pamplona de Oliveira, Tarsila Campanha da Rocha Ribeiro, Carlos Alberto Mourao Junior, Maria Antônia de Lima Barra, Mariana Hippert Gonçalves Silva, Luis Pordeus Shafee, Sarah Mendes Zacarias, Lenilton da Costa Campos, Helena Maria Giordano Valério, Júlio Maria Fonseca Chebli. Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inﬂammatory bowel disease in tertiary center. Revista da Associação Médica Brasileira 2024; 70(6) doi: 10.1590/1806-9282.20231321
4	Paulina Núñez F, Fabiola Castro, Gabriel Mezzano, Rodrigo Quera, Diego Diaz, Lorena Castro. Hepatobiliary manifestations in inflammatory bowel disease: A practical approach. World Journal of Hepatology 2022; 14(2): 319-337 doi: 10.4254/wjh.v14.i2.319 Abstract(1071) \| Core Tip(996) \| Full Article(HTML)(5263) \| Full Article (PDF)-2379K(629) \| Full Article (Word)-813K(158) \| Audio-551K(23) \| Peer-Review Report-251K(221) \| Answering Reviewers-130K(181) \| Times Cited (18) \| Total Visits (7553) \| Open
5	Rossella Maresca, Irene Mignini, Simone Varca, Valentin Calvez, Fabrizio Termite, Giorgio Esposto, Lucrezia Laterza, Franco Scaldaferri, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco. Inflammatory Bowel Diseases and Non-Alcoholic Fatty Liver Disease: Piecing a Complex Puzzle Together. International Journal of Molecular Sciences 2024; 25(6) doi: 10.3390/ijms25063278
6	Seyed Mohamad Musavi, Ali Afrasiabi. The global prevalence of non-alcoholic fatty liver disease and related terms in adults with inflammatory bowel disease: a systematic review and meta-analysis. Egyptian Liver Journal 2026; 16(1) doi: 10.1186/s43066-026-00519-2
7	Ying-Hsiang Wang, Chi-Hsiang Chung, Tien-Yu Huang, Chao-Feng Chang, Chi-Wei Yang, Wu-Chien Chien, Yi-Chiao Cheng. Association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a nationwide population‑based cohort study. Intestinal Research 2025; 23(1) doi: 10.5217/ir.2023.00078
8	Scott McHenry, Matthew Glover, Ali Ahmed, Quazim Alayo, Maria Zulfiqar, Daniel R Ludwig, Matthew A Ciorba, Nicholas O Davidson, Parakkal Deepak. NAFLD Is Associated With Quiescent Rather Than Active Crohn’s Disease. Inflammatory Bowel Diseases 2024; 30(5) doi: 10.1093/ibd/izad129
9	Iván Ferraz-Amaro, Alejandro Hernández-Camba, Marta Carrillo-Palau, Noemi Hernández Álvarez-Buylla, Antonia de Vera-González, Alejandra González-Delgado, Elena Heras-Recuero, Miguel Á. González-Gay. Liver Fibrosis Index-4 Does Not Correlate to Liver Elastography in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine 2024; 13(21) doi: 10.3390/jcm13216430
10	Min Xu, Tong Wu, Zhaoxia Li, Guijie Xin. Influence of genetically predicted autoimmune diseases on NAFLD. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1229570
11	Somtochukwu Onwuzo, Antoine Boustany, Mustafa Saleh, Riya Gupta, Chidera Onwuzo, Jessy Mascarenhas Monteiro, Favour Lawrence, Chukwuemeka Obuekwe, Zoya Morani, Imad Asaad. Increased Risk of Non-Alcoholic Steatohepatitis in Patients With Inflammatory Bowel Disease: A Population-Based Study. Cureus 2023; doi: 10.7759/cureus.35854
12	Rui Gaspar, Catarina Castelo Branco, Guilherme Macedo. Liver manifestations and complications in inflammatory bowel disease: A review. World Journal of Hepatology 2021; 13(12): 1956-1967 doi: 10.4254/wjh.v13.i12.1956 Abstract(1087) \| Core Tip(934) \| Full Article(HTML)(6027) \| Full Article (PDF)-959K(757) \| Full Article (Word)-159K(223) \| Audio-371K(20) \| Peer-Review Report-213K(198) \| Answering Reviewers-98K(219) \| Times Cited (51) \| Total Visits (8048) \| Open
13	Ya Yuan, Dazuo Wu, Heping Chen, Zheng Ma, Xinyue Peng, Xiaodie Li, Chuchu Zhao, Linping Jiang, Jinping Liang, Weiwei Zhang, Juan Dai. Farnesol ameliorates DSS-induced IBD by regulating inflammatory cytokines, repairing the intestinal barrier, reversing the gut microbiota imbalance, and influencing fecal metabolome in C57BL/6 mice. Biomedicine & Pharmacotherapy 2024; 180 doi: 10.1016/j.biopha.2024.117518
14	Ludovico Abenavoli, Lidia Giubilei, Anna Caterina Procopio, Rocco Spagnuolo, Francesco Luzza, Luigi Boccuto, Emidio Scarpellini. Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay. Nutrients 2022; 14(24) doi: 10.3390/nu14245323
15	Yuyang Zhao, Jiangbin Wang, He Sun. Prevalence of non-alcoholic fatty liver disease among inflammatory bowel disease patients: a systematic review and meta-analysis. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1517462
16	Alireza Beheshti Maal, Mohammad Amin Shahrbaf, Bahareh Sadri, Nikoo Hossein-Khannazer, Mohammad Ali Mansournia, Massoud Vosough. Prevalence of Hepatobiliary Manifestations in Inflammatory Bowel Disease: A GRADE Assessed Systematic Review and Meta-Analysis of more than 1.7 Million Patients. Journal of Crohn's and Colitis 2024; 18(3) doi: 10.1093/ecco-jcc/jjad157
17	Narsimha Keetha Rao, Shahriar Ghodous, Anoop Gurram, Mehrdad Khorasani, Madhusudhan Ponnala, Arman Habibi, Kwame Agyeman, Parsa Saberian, Pubali Biswas, Negin Letafatkar, Simran Joshi, Yasmin Sahli, Reza Amani-Beni, Bahar Darouei, Yussif Issaka, Kiran Sandilya Balivada, Farahnaz Joukar, Amir Nasrollahizadeh, Anderson Ogazi, Mohammad Amin Karimi, Michael T Ulrich, Mohammad-Hossein Keivanlou, Mohammad-Javad Khosousi, Seyyed Mohammad Hashemi, Ehsan Amini-Salehi, Sandeep S Nayak. Prevalence and Associated Factors of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Disease: An Updated Global Systematic Review and Meta-Analysis of over 1.5 Million Individuals. Inflammatory Bowel Diseases 2026; 32(2) doi: 10.1093/ibd/izaf226
18	Qijin Hong, Jun Shen, Qi Feng, Qing Zheng, Yuqi Qiao. Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02238-5
19	Ludovico Abenavoli, Rocco Spagnuolo, Giuseppe Guido Maria Scarlata, Emidio Scarpellini, Luigi Boccuto, Francesco Luzza. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study. Medicina 2023; 59(11) doi: 10.3390/medicina59111935
20	Goran Hauser, Indira Benjak Horvat, Mirjana Rajilić-Stojanović, Irena Krznarić-Zrnić, Michail Kukla, Vedrana Aljinović-Vučić, Ivana Mikolašević. Intestinal Microbiota Modulation by Fecal Microbiota Transplantation in Nonalcoholic Fatty Liver Disease. Biomedicines 2025; 13(4) doi: 10.3390/biomedicines13040779
21	Roberto Grassia, Andrea Drago, Fabrizio Cereatti, Francesca Ferretti, Biagio Elvo, Maria Chiara Verga, Sara Soro, Stefano Mazza. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World Journal of Hepatology 2021; 13(12): 1828-1849 doi: 10.4254/wjh.v13.i12.1828 Abstract(1130) \| Core Tip(1064) \| Full Article(HTML)(8441) \| Full Article (PDF)-1302K(1364) \| Full Article (Word)-246K(361) \| Audio-812K(76) \| Peer-Review Report-225K(244) \| Answering Reviewers-102K(233) \| Times Cited (18) \| Total Visits (11256) \| Open
22	Mohammad Zamani, Shaghayegh Alizadeh‐Tabari, Siddharth Singh, Rohit Loomba. Meta‐analysis: prevalence of, and risk factors for, non‐alcoholic fatty liver disease in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2022; 55(8) doi: 10.1111/apt.16879
23	D.N. Shintaku, M.A. Lopes, R.F. Beraldo, E.C.S. de Oliveira, G.S.P. Herrerias, A.C.B. de Oliveira, J.P. Baima, W.F. Barbosa, G.F. Silva, L.Y. Sassaki. Investigation of liver diseases using liver Doppler ultrasound in patients with inflammatory bowel diseases. Brazilian Journal of Medical and Biological Research 2025; 58 doi: 10.1590/1414-431x2025e14523
24	Anastasia Postoev, Abebe Yigzaw, Helai Hussaini, Olaniyi Fadeyi, Rahman Hameed Mohammed Abdul , Sonalben Chaudhary, Mohammed Qasim Rauf, Neelum Ali. Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Cureus 2025; doi: 10.7759/cureus.97094
25	Samuel J. Martínez-Domínguez, Sandra García-Mateo, Carla J. Gargallo-Puyuelo, Beatriz Gallego Llera, Engy Refaie, Pilar Callau, Carolina Mendi, Pedro M. Baptista, María Hernández Ainsa, María Teresa Arroyo-Villarino, Julia López de la Cruz, Javier Martínez-García, Erika Alfambra, Miguel Ángel Simón Marco, Javier Ampuero, Fernando Gomollón. Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease. European Journal of Internal Medicine 2024; 120 doi: 10.1016/j.ejim.2023.10.019
26	Sara Jarmakiewicz-Czaja, Aneta Sokal, Piotr Pardak, Rafał Filip, Alessandro Granito. Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology 2022; 2022 doi: 10.1155/2022/4344905
27	Elena Grueso Navarro, Alfredo J. Lucendo. Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences. Expert Review of Clinical Immunology 2025; 21(7) doi: 10.1080/1744666X.2025.2514605
28	Giovanni Tarantino, Vincenzo Citro. Crosstalk Between the Spleen and Other Organs/Systems: Downstream Signaling Events. Immuno 2024; 4(4) doi: 10.3390/immuno4040030
29	Anca Trifan, Remus Stafie, Adrian Rotaru, Ermina Stratina, Sebastian Zenovia, Robert Nastasa, Laura Huiban, Tudor Cuciureanu, Cristina Muzica, Stefan Chiriac, Irina Girleanu, Ana-Maria Singeap, Catalin Sfarti, Camelia Cojocariu, Oana Petrea, Carol Stanciu. Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter. Journal of Clinical Medicine 2022; 11(19) doi: 10.3390/jcm11195959
30	Ana Stemate, Delia-Ionela Negru-Vodă, Ana Maria Patricia Mazurencu-Pele, Remus-Florin Popescu, Teodora-Iulia Spătaru, Lucian Negreanu. Exploring the Overlap of MASLD and IBD: Insights from a Single-Center Experience. International Journal of Molecular Sciences 2025; 26(21) doi: 10.3390/ijms262110288
31	Hirsh D. Trivedi, Emily W. Lopes, Jeremy Glissen Brown, Shaan Dudani, Michelle Lai, Joseph D. Feuerstein, Theodore T. Pierce. Steroid Use and Risk of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 2023; 57(6) doi: 10.1097/MCG.0000000000001727
32	Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson. Autoimmune disease in offspring of mothers with metabolic dysfunction-associated steatotic liver disease (MASLD): a nationwide cohort study. Scientific Reports 2026; 16(1) doi: 10.1038/s41598-026-46246-x
33	Hüseyin Aykut, Nermin Mutlu Bilgiç, Duygu Demirtaş, Süleyman Sayar, Kamil Özdil. Metabolic Dysfunction-Associated Steatotic Liver Disease in Inflammatory Bowel Disease: A Cross-Sectional Study of Prevalence and Associated Factors. Metabolites 2026; 16(7) doi: 10.3390/metabo16070450
34	Pilar Navarro, Lucía Gutiérrez-Ramírez, Antonio Tejera-Muñoz, Ángel Arias, Alfredo J. Lucendo. Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease. Nutrients 2023; 15(21) doi: 10.3390/nu15214507
35	Apostolis Papaefthymiou, Styliani Sarrou, Konstantinos Pateras, Ilias D. Vachliotis, Georgios Agrotis, Ioanna-Konstantina Sgantzou, Georgios Perifanos, Andreas Kapsoritakis, Matthaios Speletas, Marianna Vlychou, George N. Dalekos, Spyros Potamianos, Antonis Goulas, Jannis Kountouras, Stergios A. Polyzos. The Effect of Biologic Agents on Steatotic Liver Disease in Patients with Inflammatory Bowel Disease: A Prospective, Open-Label Comparative Trial. Pharmaceuticals 2024; 17(11) doi: 10.3390/ph17111432
36	Lanlan Chen, Zhongqi Fan, Xiaodong Sun, Wei Qiu, Yuguo Chen, Jianpeng Zhou, Guoyue Lv. Mendelian Randomization Rules Out Causation Between Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.891410
37	Joseph-Kevin Igwe, Phani Keerthi Surapaneni, Erin Cruz, Cedric Cole, Kingsley Njoku, Jisoo Kim, Ugo Alaribe, Kelechi Weze, Bilal Mohammed. Bariatric Surgery and Inflammatory Bowel Disease: National Trends and Outcomes Associated with Procedural Sleeve Gastrectomy vs Historical Bariatric Surgery Among US Hospitalized Patients 2009–2020. Obesity Surgery 2023; 33(11) doi: 10.1007/s11695-023-06833-7